SEC Form D private-offering filing

Outlook Therapeutics, Inc.

Name: Outlook Therapeutics, Inc. - new SEC Form D private-offering filing, Iselin, NJ
Published: 2026-05-07

A new SEC Form D private-offering notice from Iselin, NJ, a $5,000,000 filer-stated offering target in Biotech. The source filing is one click away.

Outlook Therapeutics, Inc. site↗ Verified via SEC Form D

Clinical-stage biopharmaceutical company developing LYTENAVA (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for wet age-related macular degeneration and other retinal diseases.

Filed 2026-05-07Filed to raise $5,000,000First money in 2026-04-23HQ (as filed) Iselin, NJSector Biotech ✓Stage (inferred) EarlyCall status No reported sale

Source linked the Form D on EDGAR↗Website verified outlooktherapeutics.com↗Named in the filing 8 executives & directors

Open this row on the live feed →More new filings in New Jersey →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.